Charles River Laboratories International (NYSE:CRL) EVP Sells $1,038,657.24 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 3,714 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.66, for a total transaction of $1,038,657.24. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,344,325.62. The trade was a 43.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Down 0.9%

NYSE:CRL traded down $2.59 during trading hours on Thursday, reaching $281.78. The company’s stock had a trading volume of 1,054,824 shares, compared to its average volume of 929,021. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The company has a market cap of $13.45 billion, a price-to-earnings ratio of -58.10, a price-to-earnings-growth ratio of 2.92 and a beta of 1.38. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $288.02. The business’s 50-day moving average is $220.98 and its 200-day moving average is $190.27.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Cardinal Capital Management boosted its holdings in Charles River Laboratories International by 0.6% in the 4th quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after purchasing an additional 62 shares during the period. Asset Management One Co. Ltd. raised its position in shares of Charles River Laboratories International by 4.0% during the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after buying an additional 71 shares during the last quarter. Glenmede Trust Co. NA raised its position in shares of Charles River Laboratories International by 2.8% during the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after buying an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after buying an additional 80 shares during the period. Finally, Advisory Services Network LLC lifted its stake in shares of Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after buying an additional 83 shares during the period. 98.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CRL shares. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 1st. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research note on Monday, July 20th. Finally, Morgan Stanley lifted their target price on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.